IPSEN PHARMA

History

Year	Detail
1929	Dr. Henri Beaufour founded the Beaufour Laboratories in Dreux.
1975	Laboratoires Beaufour created a subsidiary and began to internationalize its activities.
1983	The group created the Fondation Ipsen under the aegis of the Fondation de France to encourage exchanges between scientists in life sciences.
1994	The group launched Dysport (type A botulinum toxin for treating muscle spasms) after acquiring the British company Speywood (then called Porton International).
1995	The group launched Somatuline, which treats hypersecretion of growth hormones (acromegaly) in neuroendocrine tumors.
2003	The company changed its name to Ipsen.
2007	The company partnered with Galderma to produce botulinum toxin type-A products in aesthetic medicine.
2011	Ipsen announced a new strategy focusing on several areas, including a refocus on specialty medicine, research and development, and international development.
2013	Ipsen acquired Syntaxin, a leader in the engineering of recombinant botulinum toxin, for $37 million. The acquisition was seen as a way for Ipsen to strengthen its position in botulinum toxin-based therapies.
2019	Ipsen acquired Clementia Pharmaceuticals, which specializes in rare bone diseases. Clementia brought a drug candidate, palovarotene, to Ipsen for a rare genetic disease, fibrodysplasia ossificans progressiva (FOP).
2022	Ipsen announced the proposed sale of the Consumer HealthCare (CHC) division after entering into exclusive negotiations with the French laboratory Mayoly Spindler.
2022	Ipsen-acquired Tazverik (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor for adults with relapsed or refractory Follicular Lymphoma (FL), was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.
2023	Ipsen acquired rare liver disease specialist Albireo, bringing into its portfolio Bylvay (odevixibat), a non-systemic ileal bile acid transport inhibitor for the treatment of pediatric patients with pruritus in progressive familial intrahepatic cholestasis (PFIC).